Granules India Receives USFDA EIR for Bonthapally Facility
Granules India Limited, a pharmaceutical manufacturing company, has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its API Unit-I facility located at Bonthapally, Hyderabad.
The news was reported by Medical Dialogue, with correspondents Ruchika Sharma and Chief Editor Dr. Kamal Kant Kohli leading the coverage of pharmaceutical news and updates.
No additional comments were provided by the company or the FDA.
Author's summary: Granules India receives USFDA EIR approval.
- Company: Granules India Limited
- Facility: API Unit-I, Bonthapally, Hyderabad
- Regulatory body: U.S. Food and Drug Administration (FDA)
More News
- How Discrimination and Stress Impact the Mental Health of Young Sexual Minority Men
- Israeli Colonizers Invade Bedouin Village Near Jerusalem
- Most Exciting Prospects for 2026: AL Central
- Uzbekistan pitches worldwide initiatives at UNESCO General Conference
- An Obscure Military Program Helps Local Cops Buy Armored Cars and Spyware. It Might Balloon Under Trump.
- Emmy-Winner Chronicles Yankees Icon Joe Torre’s MLB Legacy On Screen
- Prime Minister Pashinyan should be excommunicated and arrested
- Record Job Cuts at Amazon and UPS. AI and Reorganization Changing the Face of Logistics
- THE LATIN AMERICA DIARIES ENTRY VIII: What makes you local? - Tracks Magazine
- Trump Goes Full Dictator With Bonkers Threat to Use Air Force and Navy in U.S. Cities